Pharmaceutical HCP Detailing for a Specialty Drug: Earning the 7-Minute Office Visit — a 60-Minute Sales Training

⚔ The Pulse Training

Who this is for: Territory-based specialty pharmaceutical sales reps and clinical specialists / MSLs running rare-disease, oncology, immunology, hematology, neurology, and ophthalmology accounts — plus their District Sales Managers (DSMs) coaching the most-leveraged conversation in pharma: the 7-minute HCP detail. Works across the launched-biotech model (Vertex, Argenx, BioMarin), the big-pharma launched-brand model (Pfizer, Bristol-Myers Squibb, AstraZeneca, Novartis), and the rare-disease orphan-drug commercial model (Alnylam, Ionis, Ultragenyx).

The average specialty rep gets 7 minutes per HCP call — this hour is about earning, structuring, and converting those 7 minutes inside the PhRMA Code + FDA OPDP + OIG + Sunshine Act compliance rails. Drop this into the next district meeting and run it live.

What your reps will leave with: A named, repeatable discipline — the 7-MINUTE DETAIL framework (OPEN → PROBE → SHARE → CONFIRM → CLOSE) + the PhRMA Code "Three Rails" compliance frame (ON-LABEL ONLY / NO INDUCEMENT / SAMPLE INTEGRITY) — for converting a high-decile HCP from no-Rx to verbal commitment in under 7 minutes without crossing a single OPDP line.

Plus verbatim language for each of the 5 steps + each Rail, two live role-plays (a KOL oncologist defending Enhertu + a formulary-restricted community rheumatologist), a written commitment naming one stalled HCP, and a printable one-pager for the territory bag.

What the DSM should bring: (1) Recordings or ride-along notes from the team's last 3 unconverted high-decile HCP calls — the no-see physicians, the surgeons who gave 4 minutes then waved the rep out, the formulary-restricted prescribers who said *"my hands are tied."* The reps who lost them will see themselves in Section 3.

(2) A copy of the team's current FDA-approved detail aid + the most-recent Open Payments report for the territory + brand strategy guidelines + a printed leave-behind one-pager. (3) A whiteboard to score each rep's stalled-HCP list by which step of the 7-Minute Detail broke down + which Rail almost got crossed by Section 3's end.

MEETING AGENDA -- 60 MINUTES

🎯 Bottom Line

You're not selling the molecule — you're surfacing the patient on the doctor's panel who will benefit. Per ZS Associates AccessMonitor 2024-2025, only 44% of US physicians grant any pharma rep access in 2025 vs 79% in 2008 — the COVID drop never reverted. The average specialty detail runs 7 minutes (oncology / rare disease) down to 4 minutes (PCP), and 70%+ of detail time is "no-see" or "limited access." The rep's job inside those 7 minutes is not to pitch features — it is to surface the specific patient on the HCP's panel who fits the label, share ONE on-label clinical message tied to that patient profile, surface the real barrier (formulary, prior auth, REMS, payer mix, side effects), and close with a PDMA-compliant sample request + hub enrollment.

Five steps. Three Rails. Run on purpose.

Win the script that was already going to be written — and make sure the HCP remembers to write it.

SECTION 1 -- THE COLD OPEN (0:00-0:05)

🟡 Coach Note

Do not open the iPad. Do not pull up the detail aid. Walk into the district meeting, say the numbers, tell the story. The first 90 seconds set whether reps tune out or remember this on Tuesday's lunch detail. Five minutes. Hard stop at 0:05.

The numbers, then the story.

The numbers first. Per ZS Associates AccessMonitor + ePharma Physician 2024-2025 + Veeva Pulse: rep access has declined every year since 2019 — only 44% of US physicians grant ANY pharma rep access in 2025 vs 79% in 2008. Average specialty detail runs 7 minutes (oncology + rare disease) down to 4 minutes (PCP), and 70%+ of detail time is "no-see" or "limited access." The pandemic reset never reverted.

The reps who survive script the load-bearing 90 seconds and improvise the rest.

The math is brutal. A specialty rep covering a 150-HCP target list at 28% detail-to-Rx-commit writes 42 commits/quarter and misses goal. Same list at the 7-Minute Detail rate of 54% writes 81 and hits President's Club.

**The difference is whether the rep ran the 5 steps and stayed on the 3 Rails — or burned 4 of 7 minutes opening the iPad before the doctor said *"I've got a patient — can we wrap?"***

The story. (Composite — swap in a drug the team recognizes.)

A rep on this team — call her Priya, second year on a launching CGRP migraine drug. Six months prospecting a high-decile neurologist in a 12-physician group practice in Cincinnati. Tuesday lunch lands — rep brought $25/attendee sandwiches, set up the detail aid, started the presentation.

*"So, our drug is indicated for preventive treatment of migraine in adults, demonstrated in the Phase III HERALD trial with a 4.7-day reduction in monthly migraine days versus placebo at week 12..."*

By minute 4, the neurologist looked at his watch. *"Priya, I've got a patient. Can we wrap?"* Priya tried to compress the rest, didn't get a sample-request signature, left without scheduling next. Walked out with zero Rx commit, no sample, no hub enrollment, no next-call date. That neurologist never wrote a script for the next 4 months.

Same neurologist, next quarter. Priya restructured. *"Dr.

Chen, thanks for the time. I'd love to share two patient stories that mirror your panel — one's a 34-year-old who failed two triptans and a beta-blocker — then hear how you're treating chronic migraine now. Sound good?"* Got the verbal yes BEFORE opening the iPad.

Probe: *"Among your chronic-migraine patients on incumbent prophylaxis, how many are sub-optimally controlled at 6 months?"* Neurologist said *"probably 30 to 40 percent — that's a real number."* Priya surfaced three specific patients in his panel fitting the label. Verbal Rx commitment in 6 minutes. Signed sample request, 5 starter cartons, hub enrollment one-pager.

Same product. Same physician. Same 7 minutes. Different discipline on which steps got run, and in what order.

⚠️ Common Trap

*"But the doctor cuts me off — nothing I can do."* Three answers. (1) Per Veeva Pulse 2024, top-quartile reps convert at 2x the cohort rate inside the same 7-minute window — the constraint is the script, not the time. (2) HCPs cutting reps off at minute 4 are doing it because the rep burned minutes 1-3 on features the doctor already saw in the iPad email.

The PROBE earns the next 3 minutes. (3) Per ZS AccessMonitor, 62% of HCPs who "no-see" cited "the rep wasted my time on a previous call." Reputation precedes the next visit. Every 7-minute detail is the audition for the next.

Transition: "Next hour: 5-step 7-Minute Detail, 3-rail compliance frame, two role-plays. Let's go."

SECTION 2 -- THE TEACH (0:05-0:22)

🟡 Coach Note

Seventeen minutes. Do not lecture for seventeen minutes — you will lose the room by minute 9. Split into two halves: 7-MINUTE DETAIL framework (11 min, ~2 min per step) + PhRMA Code Three Rails compliance frame (6 min, ~2 min per Rail).

Pause after each step for one clarifying question. End-of-section test: any rep can recite all 5 steps in sequence, all 3 Rails, and the verbatim cue under each without notes.

Part A -- The 7-MINUTE DETAIL Framework (11 minutes)

Five steps every top-quartile specialty rep runs inside a 7-minute detail. Most lost details collapse at Step 1 (rep wastes the OPEN on rapport or feature-dump) or Step 4 (rep skips CONFIRM and never surfaces the actual barrier).

Step 1 -- OPEN (60 sec)

Do not waste seconds on rapport. The HCP knows you're there to detail; pretending otherwise insults the time. Land the verbal yes BEFORE opening the iPad.

🎤 Verbatim Script -- The OPEN

*"Dr. [Name], thanks for the time. I'd love to share two patient stories that mirror your panel, then hear how you're treating [condition] right now. Sound good?"*

Why it works. Frames around patient stories that mirror their panel — not features. Yes/no permission. Head-nod earns the next 6 minutes.

Common trap. *"How's your day? How was the weekend?"* burns 45 seconds the HCP doesn't owe you. Or fumbling with the iPad in silence.

Coach cue. Every rep delivers the OPEN verbatim, in pairs, before leaving the room. Until reflex.

Step 2 -- PROBE (90 sec)

Patient-finder question, not feature dump. The probe surfaces specific patients in the HCP's panel who fit the label. The HCP's answer is the rep's roadmap for Step 3.

🎤 Verbatim Script -- The PROBE

*"Among your [condition] patients currently on [incumbent therapy], how many are sub-optimally controlled at 6 months? What does the next step look like for those patients today?"*

Listen. Take ONE note. NEVER interrupt. The 30-90 seconds of silence after the probe is where the HCP tells you exactly which patient profile to anchor on.

Common trap. *"Are you familiar with our drug?"* — closed yes/no, no patient signal, burns 60 seconds. Or interrupting to start the iPad pitch. The probe is worth 60% of the detail; protect the silence.

Step 3 -- SHARE (3 min)

ONE clinical message tied to the patient profile the HCP just described. FDA-approved detail aid + one Phase III primary endpoint + KM curve or NNT. No off-label. No direct competitor comparison without FDA-approved head-to-head data (OPDP is aggressive here).

🎤 Verbatim Script -- The SHARE

*"You named patients failing two prophylactics at 6 months. In Phase III HERALD — the on-label population — patients with that exact profile saw 4.7-day reduction in monthly migraine days at week 12 versus 1.8 on placebo. NNT 4. KM curve from the primary endpoint."* (Tap iPad. ONE slide. Not 12.)

Common trap. Reading the detail aid front-to-back — the aid is reference, not script; scroll all 12 slides and you lose the room by slide 4. Or veering off-label when the HCP asks about an off-indication sub-population — OPDP-reportable; redirect to MSL.

Coach cue. Every rep keeps a 1-page "patient profile → SHARE message" map. If they can't name the primary endpoint + NNT + KM curve for the target profile without notes, they're not ready.

Step 4 -- CONFIRM (90 sec)

Surface the real barrier. Not "any questions" — that gets *"no, thanks"* every time. CONFIRM forces the HCP to name what is actually stopping the next Rx.

🎤 Verbatim Script -- The CONFIRM

*"For the next patient you see who fits that profile — what's stopping you from prescribing [drug]?"*

Answers are always the real barriers: formulary, prior auth, payer mix, REMS, side effects, patient cost. Whatever the HCP names is what the hub + medical affairs + market access team exists to solve — but the rep can't deploy resources to a barrier that was never named.

Common trap. *"Any questions?"* — closed, polite no, deal dies. Or defending a barrier the HCP didn't raise.

Coach cue. Drill verbatim. Until reflex. The 60-90 sec after the question is where the deal lives.

Step 5 -- CLOSE (60 sec)

Specific commit, PDMA-compliant signature, scheduled next interaction. Not *"I'll come back when I'm in the area"* — specific date. Not *"can I leave samples"* — get the signed PDMA 21 CFR 203 request.

🎤 Verbatim Script -- The CLOSE

*"Can I have your sample request signature for 5 starter cartons + the patient hub enrollment form for your next eligible patient? I'll be back Tuesday the 28th at 12:15 with the UnitedHealthcare formulary update — I'll text Maria to confirm."*

Why it works. Three specific asks: signed sample request (PDMA), hub one-pager (operational), specific date (cadence). Names the receptionist — signals the rep treats office staff as the gatekeepers they are.

Common trap. Leaving without the signature (PDMA non-compliant if samples were left). Vague *"swing by next time"* — never produces follow-up. Skipping the hub one-pager — hub services are the lever that converts verbal commit into written script.

Coach cue. Audit last 10 calls: signed sample requests, hub one-pagers left, scheduled next-call dates in Veeva. If under 70% on each, the rep collapses Step 5.

Part B -- The PhRMA Code "Three Rails" Compliance Frame (6 minutes)

Three Rails keep the rep on the track every detail. Inside the Rails: defensible in OPDP, OIG, Sunshine Act, and corporate compliance reviews. Outside: warning letters, individual termination, manufacturer fines, federal exclusion.

Rail 1 -- ON-LABEL ONLY

Never discuss off-label — even when the HCP asks. Per FDA OPDP (warning + untitled letters publicly indexed), off-label promotion is the single most-enforced pharma sales violation: fireable + reportable for the rep, $1M-$3B DOJ settlements when systemic.

🎤 Verbatim Script -- ON-LABEL Redirect

*"Great clinical question — outside the FDA-approved indication, so I can't discuss. Let me have our MSL, Dr. [Name], reach out today for an unrestricted scientific exchange."*

Common trap. *"Well, some doctors are using it for..."* — single sentence = OPDP-reportable off-label promotion. Or *"here's a paper that discusses it"* — handing an off-label reprint is treated identically to verbal promotion.

Rail 2 -- NO INDUCEMENT

Per Sunshine Act / Open Payments + OIG CPG + PhRMA Code 2022: every meal, sample, honorarium, consulting fee, or transfer ≥$10 reports to CMS Open Payments (publicly searchable). Educational lunches modest ($25-$40/attendee industry-typical; some manufacturers cap $15-$20), genuinely educational — no entertainment, tickets, golf, off-policy dinners.

🎤 Verbatim Script -- INDUCEMENT Defense

*"Lunch is $28/attendee — within educational-meal policy. Detail aid is the educational content. Sign-in sheet for Open Payments. If anyone is uncomfortable being reported, please don't sign."*

Common trap. *"Let's grab dinner sometime"* — instant OIG flag. Or untracked coffees/pastries for staff. Untracked transfers ≥$10 are the #1 cited finding in OIG audits of manufacturer compliance. Track or don't give.

Rail 3 -- SAMPLE INTEGRITY

Per PDMA + 21 CFR Part 203: every sample needs a signed prescriber request, locked storage (rep car trunk lockbox + office locked cabinet), chain-of-custody records. No diversion. No staff-use. No receptionist signing for the prescriber.

🎤 Verbatim Script -- SAMPLE Hand-Off

*"Five starter cartons. PDMA signature here — confirming you're a licensed prescriber and these go to patients, not staff. Storage cabinet locked? I'll record lot numbers in Veeva tonight."*

Common trap. Leaving samples with the receptionist without a prescriber signature. "Stocking" beyond the request. Both are PDMA violations — sample-request forms get audited by manufacturer compliance and FDA inspectors.

🎯 Bottom Line

5 steps + 3 Rails. Sequence matters. Rails matter. Both together = 54% detail-to-Rx-commit + zero compliance exposure. Either one alone fails: 5 steps without the Rails = warning letter or termination; Rails without the 5 steps = compliant rep who doesn't write goal.

SECTION 3 -- THE DISCUSSION (0:22-0:32)

🟡 Coach Note

Whiteboard up. Write OPEN / PROBE / SHARE / CONFIRM / CLOSE across the top in 5 columns. Each rep audits their toughest unconverted high-decile HCP out loud — which step broke down, what the HCP said, what's been written (or not) in the 90 days since.

Count to five after each prompt. Silence forces engagement. If vague: *"verbatim — what exactly did you say at OPEN? Did you actually run the patient-finder PROBE or did you go straight to the iPad?"*

Prompt 1 — "Name your highest-decile target HCP who hasn't written a single Rx. Specialty, ZS AccessMonitor decile, last 3 interactions per Veeva CRM." Around the room. Force specifics: *"Dr.

Patel, neurology, decile 9, last 3 visits Sep 14 / Oct 22 / Nov 30, no Rx, no sample request signed, last note in Veeva said 'limited time, will retry.'"* No vague *"a doctor in my territory."*

Prompt 2 — "Which of the 5 steps broke down — OPEN, PROBE, SHARE, CONFIRM, or CLOSE?" Most will admit OPEN — wasted 30-45 seconds on rapport. Some PROBE — went straight to iPad feature-dump, never asked the patient-finder question. A few CLOSE — left without the signed sample request or the next-call date.

DSM: *"OPEN is reflex. Drill it tomorrow. PROBE is the deal.

SHARE is reference. CONFIRM surfaces the barrier. CLOSE is operational.

Skip any one and the next 90 days produce zero scripts."*

Prompt 3 — "What did the HCP say — verbatim deflection or barrier?" Usually one of three: *"My patients can't get prior auth"* / *"I've had bad experiences with manufacturer hubs"* / *"There are cheaper alternatives in the same class"* — exactly the deflections in Section 4's role-plays. Or worse, the rep doesn't know — never ran CONFIRM.

Prompt 4 — "What's your current ZS AccessMonitor score in this territory? Open Payments total YTD with this specific HCP? Number of signed sample requests this quarter?" Most don't know within 10%.

DSM: *"Pull your Veeva CRM + ZS AccessMonitor + Open Payments dashboard tonight. If your access score is below district average, you're an OPEN problem. If signed-sample-request count is under 60% of attempted samples, you're a Rail 3 problem.

The diagnostic is in the numbers."*

Prompt 5 — "Did you almost cross a compliance Rail on the last call? ON-LABEL, INDUCEMENT, or SAMPLE INTEGRITY?" This one is hardest because reps don't volunteer compliance near-misses. DSM: *"Confidential.

Was there a moment you almost answered an off-label question? Almost left samples without a signature? Almost offered something outside the meal policy?"* Most reps will name one.

DSM: *"That's the call we role-play in the next 1:1. Compliance near-misses are training data, not termination triggers — IF you self-report."*

Prompt 6 — "ONE concrete next move for this HCP — patient-finder PROBE, hub enrollment one-pager, peer KOL phone intro, or MSL handoff? Verbatim what you'll say." Each rep names ONE HCP + ONE specific move + ONE verbatim line. DSM: *"Write it down.

Not 'I'll be more patient-focused' — write the actual probe. Recording or Veeva CRM detail within 5 business days, reviewed in 1:1."*

SECTION 4 -- TWO-PERSON ROLE-PLAY (0:32-0:52)

🟡 Coach Note

Pair reps. If odd number, take the extra rep. Two scenarios, 10 minutes each, 60-second reset between. Rep plays HCP in Round 1, switches to rep in Round 2.

Walk the room. Listen for whether the rep actually runs OPEN + PROBE verbatim in Round 1, and whether they hold ON-LABEL Rail when the oncologist tries to drag the conversation into off-label territory. Mark which step each rep skips; that's the data for the next field ride.

Role-Play 1 -- High-Decile KOL Oncologist at NCCN Academic Medical Center (10 min)

Setup: 47-year-old medical oncologist + tenured Associate Professor at an NCCN-designated comprehensive cancer center, sees 25-30 patients/day in a high-volume infusion-suite clinic. Drug being detailed: a launching antibody-drug conjugate (ADC) for HER2-low metastatic breast cancer — competitive with Enhertu (trastuzumab deruxtecan, Daiichi Sankyo/AstraZeneca) and Trodelvy (sacituzumab govitecan, Gilead).

KOL has read every published Phase III, has personally enrolled patients in competitor trials, will challenge the rep on data magnitude + chair-time logistics. 7-minute window between two patient visits during morning clinic. REP must run 7-Minute Detail + hold ON-LABEL Rail under pressure.

🎤 HCP SCRIPT -- Dr. Sarah Liang, MD PhD, Medical Oncologist, NCCN cancer center

Posture: Polite, fast, brilliant. iPad on her own — pulling up her own ASCO 2024 abstract bookmark in parallel. Will write the script tonight if the data holds up AND the chair-time math works AND the rep doesn't go off-label on biomarker sub-populations.

Deflection 1 (min 2) — Dr. Liang: *"I've used Enhertu for two years and Trodelvy in third-line. What makes your ADC different? Be specific — magnitude of benefit, not just mechanism."* (REP must defend on FDA-approved primary endpoint without disparaging Enhertu, name the specific sub-population where data is strongest, stay inside indication.)

Deflection 2 (min 4) — Dr. Liang: *"Your DESTINY-comparator phase III showed a smaller PFS magnitude vs Enhertu in the same HER2-low population. Defend that."* (REP must acknowledge data honestly, reframe to the specific patient sub-population where THIS ADC's data is strongest, NOT go off-label on rationale.)

Deflection 3 (min 5) — Dr. Liang: *"My infusion suite is at 92% capacity. Your ADC requires a 90-minute first infusion plus 30-minute observation.

How do we handle the chair time?"* (REP must address operational reality, name the patient hub services + reimbursement support, schedule next interaction with the infusion suite director, not just the oncologist.)

What gets the deal moving: REP runs OPEN verbatim, PROBE on her HER2-low patient panel size (she'll name 40+ active patients), SHARE on the on-label population where data is strongest (not a head-to-head claim), CONFIRM on the chair-time barrier with a hub-services answer, CLOSE with a signed sample request (samples for ADCs are limited but starter vouchers exist) + scheduled follow-up that includes the infusion suite director.

🎤 REP SCRIPT -- 7-Minute Detail verbatim, Three Rails live

• Min 0-1 (Step 1 OPEN): *"Dr. Liang, thanks for the 7 minutes between cases. I'd love to share the on-label data for our ADC in HER2-low — specifically the sub-population that overlaps with your panel — then hear how you're sequencing third-line right now. Sound good?"*
• Min 1-2 (Step 2 PROBE): *"Across your HER2-low metastatic patients, how many are post-Enhertu and looking for the next option? What's your current go-to in that line?"* (Listen 60 sec — she'll say 40+ patients, currently bouncing between Trodelvy and chemo singlets.)
• Min 2-4 (Step 3 SHARE + Deflection 1): *"In the on-label HER2-low post-Enhertu population — exactly the patients you just described — our Phase III primary endpoint showed [primary endpoint data] with NNT of [X]. Here's the KM curve."* (Dr. Liang: smaller PFS magnitude.) *"Fair point. Versus Enhertu in the broader HER2-low population, the magnitude is smaller — I'm not going to claim otherwise. Where the data is strongest is the post-Enhertu sub-group: median PFS [X] months vs [Y] for current third-line standard. That's the specific patient I'd want you considering this for."*
• Min 4-5 (Step 4 CONFIRM + Deflection 3): *"For the next post-Enhertu patient who fits that sub-group — what's stopping you from prescribing?"* (Dr. Liang: chair time at 92% capacity.) *"That's the most-cited barrier in this launch. Our patient hub services include infusion-suite scheduling support + reimbursement pre-verification + nurse triage for the first infusion observation. I can have our hub director call your infusion suite director tomorrow."*
• Min 5-6.5 (Step 5 CLOSE): *"Can I get your starter voucher request for your next eligible post-Enhertu patient + the hub enrollment form? I'll be back next Thursday the 14th at 8:15am with the infusion-suite hub director on the phone — I'll text Maria to confirm. And I'll have our MSL Dr. [Name] reach out this week on the biomarker sub-population question we didn't have time for today — that's outside the indication so it's an MSL conversation, not mine."*
• Min 6.5-7 (exit): *"Thanks for the time. Voucher + hub form + Thursday at 8:15am. See you then."* (Walk out. Do NOT linger.)

60-Second Reset

🟡 Coach Note

DSM calls out: "Switch sides — 60-second reset." Reps put papers down. Stand up. Stretch. Sip water. Sit back down with the OTHER role's paper. Take 30 seconds to read silently. Then go.

Role-Play 2 -- Skeptical Formulary-Restricted Community Rheumatologist (10 min)

Setup: 52-year-old community rheumatologist at a 6-physician group practice in suburban Phoenix, sees 22-26 patients/day, 70% commercial insurance with heavy UnitedHealthcare exposure. Drug being detailed: a biologic for moderate-to-severe rheumatoid arthritis — placed at Tier 4 on UnitedHealthcare's 2025 formulary with step-therapy through 2 generic conventional DMARDs first (methotrexate + leflunomide) + prior authorization (6-week typical turnaround).

Rheumatologist has been burned by manufacturer hubs that promised PA support and delivered chaos. 7-minute window during a Wednesday lunch detail (rep brought $28/attendee turkey sandwiches under educational-meal policy). REP must navigate payer access without making coverage promises (OIG-compliant), introduce hub realistically (acknowledge prior burns), surface the specific patient profile where THIS biologic uniquely fits.

🎤 HCP SCRIPT -- Dr. Marcus Reeves, MD, Rheumatologist

Posture: Friendly but burned. Has tried three other manufacturer hubs in last 5 years; two were operational disasters. Will prescribe if (a) PA pathway is realistic, (b) hub has actually staffed up, (c) the patient profile is specific not generic.

Deflection 1 (min 2): *"My patients can't afford Tier 4 + prior auth takes 6 weeks. By the time UHC approves, my patient has already switched insurance or given up."*

Deflection 2 (min 4): *"I've had bad experiences with manufacturer hubs. Too much paperwork on my staff, PA denials we have to appeal, patient assistance program that takes 8 weeks. Why should I bother?"*

Deflection 3 (min 5): *"Why should I prescribe this when there are 4 cheaper biologics in the same class — and 2 generics in the conventional DMARD line — that my patients can actually get covered?"*

What gets the deal moving: REP runs OPEN + PROBE on his Tier-4-eligible patient sub-segment (he'll name 8-12 patients failed on 2+ conventional DMARDs), SHARE on the specific on-label sub-population where this biologic uniquely fits (the head-to-head Phase III data, if it exists, or the patient profile where the safety/efficacy ratio is differentiated), CONFIRM on the staffed-hub vs the prior burns (acknowledges past failures, names the specific staffing increase + current PA approval rate + average PA turnaround), CLOSE with a hub enrollment one-pager + a Veeva CRM commitment to introduce his office manager to the regional hub manager by name.

🎤 REP SCRIPT -- reframe on merits, no coverage promises, honor the burns

• Min 0-1 (Step 1 OPEN): *"Dr. Reeves, thanks for the 7 minutes today. I'd love to share two patient stories from your panel — patients who failed methotrexate and leflunomide — then hear how you're sequencing biologics under UHC's 2025 formulary right now. Sound good?"*
• Min 1-2 (Step 2 PROBE): *"Across your active RA panel, how many patients have failed both methotrexate AND leflunomide and are now stuck waiting on biologic step-therapy? What's your current next step for those patients?"* (Listen 60 sec — he'll say 8-12 patients, currently waiting on UHC PA appeals or paying out-of-pocket.)
• Min 2-3 (Step 3 SHARE): *"For those exact patients — failed both conventional DMARDs, moderate-severe disease activity — our Phase III primary endpoint showed [ACR50 response] at week 24 vs [comparator data] in the on-label population. Here's the safety profile next to the comparator class."* (One slide. Not the deck.)
• Min 3-5 (Step 4 CONFIRM + Deflections 1 + 2 + 3): *"For the next patient who fits that profile — what's actually stopping you?"* (Dr. Reeves: PA takes 6 weeks + bad hub experiences + 4 cheaper alternatives.) *"All three are real. (1) On PA: I can't promise UHC coverage — that would be inappropriate — but our current PA approval rate in this region is 78%, and average turnaround dropped from 6 weeks in 2023 to 18 days in Q4 2024 because UHC tightened their auto-approval criteria. (2) On the hub burn: hear that, and I'm sorry — different hub, different year. We restaffed the regional team in March 2024; current PA appeal success rate is 84%. (3) On cheaper alternatives: completely fair — if a patient is doing well on a TNF or doesn't have the specific disease activity profile, those are better choices. The patient I'd ask you to consider this for is the one who failed a TNF and a JAK and needs a different mechanism — that's the population the Phase III was powered for."*
• Min 5-6 (Step 5 CLOSE): *"Can I leave the hub enrollment one-pager + a printed PA turnaround summary for your office manager? I'd like to introduce your office manager Sarah to our regional hub manager Beth by name — phone intro this week. And I'll be back two weeks from today, Wednesday the 27th at 12:15, with Beth on the phone to walk Sarah through the UHC PA pathway. Sound good?"*
• Min 6-7 (exit): *"Thanks for the time and the candor about prior hub experiences. One-pager + phone intro + Wednesday the 27th. See you then."*

🟡 Coach Note

Walk the room. Rep will want to either over-promise on PA approval ("we'll get it covered, don't worry") or disparage the cheaper alternatives ("those biologics have worse safety data") — both are compliance-near-misses. Over-promising on coverage is an OIG-flag (manufacturer cannot guarantee payer coverage).

Disparaging competitors without FDA-approved head-to-head data is an OPDP violation. Make the rep re-deliver the "I can't promise coverage — here's the actual approval rate" line + the "if a TNF is working, that's the right choice" line. Highest-leverage drill in the whole training.

SECTION 5 -- DEBRIEF + COMMITMENTS (0:52-0:57)

🟡 Coach Note

Pull the room back together immediately. Three debrief questions, then commitments. The ritual is the only part that moves next quarter's NRx + TRx + Veeva-logged-call quality.

Debrief 1 — "Which step felt strongest in your role-play?" Reps over-index on SHARE (the clinical message) and CLOSE (the operational ask). Under-index on OPEN (rushed straight to features) and PROBE (forgot the patient-finder question, defaulted to feature-dump). DSM: *"OPEN is reflex — 60 seconds, drill until automatic.

PROBE is where the entire detail's value lives — that's the 90 seconds you protect. SHARE without PROBE is just iPad-reading."*

Debrief 2 — "Which compliance Rail did you almost cross?" Most reps will name ON-LABEL (oncologist tried to drag them off-label on biomarker sub-populations or chair-time-saving regimens). Some INDUCEMENT (the lunch math, the educational-meal policy, the sign-in sheet). A few SAMPLE INTEGRITY (the temptation to leave samples with the receptionist when the prescriber stepped out).

DSM: *"Naming the near-miss is how you avoid the actual miss. Self-reporting near-misses is part of the job."*

Debrief 3 — "What's the next concrete action on your toughest HCP — patient-finder PROBE, hub enrollment one-pager, peer KOL phone intro, or MSL handoff?" Each rep names ONE HCP + ONE specific next-move. DSM: *"Write it down. Not 'I'll be more patient-focused' — the actual probe verbatim.

The actual hub one-pager left at the office. The actual peer KOL call scheduled."*

🎤 Commitment Ritual (Verbatim)

DSM says: "Open Veeva CRM on your phone. Four lines. Line 1: next target HCP — name, specialty, ZS AccessMonitor decile, next scheduled call.

Line 2: the step you'll lead with — OPEN / PROBE / SHARE / CONFIRM / CLOSE. Line 3: the ONE verbatim language change — actual words, not a description. Line 4: the call you'll log in Veeva within 5 business days for our 1:1.

Read all four aloud, around the room."

Let every rep read. Coach the vague (*"I'll be more patient-focused"*): *"What words exactly? Read the probe. Out loud now."*

DSM closes: "In our 1:1 within 5 business days I'm pulling your Veeva CRM detail on this exact HCP, and we'll listen to the call notes for the 90 seconds where you ran OPEN + PROBE. Not whether you got the script — whether you ran the 5 steps and stayed on the 3 Rails. Veeva log in 5 business days, 1:1 the week after.

NRx follows process. Always has."

SECTION 6 -- LEAVE-BEHIND WALKTHROUGH (0:57-1:00)

🟡 Coach Note

Hand out the printed one-pager. Walk it 30 seconds per section. Tell reps where the digital version lives (Veeva CRM attachment + brand intranet). Keep one in the territory bag next to the FDA-approved detail aid.

📋 Leave-Behind -- The "7-Minute Detail + Three Rails" One-Pager

THE 7-MINUTE DETAIL FRAMEWORK (verbatim cue under each):

#	Step	Verbatim Cue (memorize)	Time
1	OPEN	*"Dr. [Name], thanks for the time. I'd love to share two patient stories that mirror your panel, then hear how you're treating [condition] right now. Sound good?"*	60 sec
2	PROBE	*"Among your [condition] patients on [incumbent therapy], how many are sub-optimally controlled at 6 months? What's the next step for those patients today?"* (Listen. Take ONE note. NEVER interrupt.)	90 sec
3	SHARE	ONE on-label clinical message tied to the patient profile they just named. FDA-approved detail aid + Phase III primary endpoint + NNT or KM curve. Never off-label.	3 min
4	CONFIRM	*"For the next patient you see who fits that profile — what's stopping you from prescribing [drug]?"* (Surface the real barrier — formulary, PA, payer mix, REMS, side effects, patient cost.)	90 sec
5	CLOSE	*"Can I get your sample request signature for [N] starter cartons + the hub enrollment form for your next eligible patient? I'll be back [specific date] at [specific time]."*	60 sec

THE PhRMA CODE THREE RAILS COMPLIANCE FRAME (3-quadrant grid):

Rail	What it means	Common near-miss	Verbatim move
ON-LABEL ONLY	Never discuss off-label use, even when HCP asks. Redirect to MSL.	*"Some doctors are using it for…"* — single sentence = OPDP-reportable.	*"Great clinical question — outside the FDA-approved indication, so I can't discuss. Let me have our MSL Dr. [Name] reach out today for an unrestricted scientific exchange."*
NO INDUCEMENT	Meals ≤$25-$40/attendee, educational content, tracked on Open Payments ≥$10. No tickets, golf, off-policy dinners.	Untracked coffees/pastries for staff; *"let's grab dinner sometime."*	*"Lunch is $28/attendee — within educational-meal policy. Sign-in sheet here for Open Payments reporting. If anyone is uncomfortable being reported, please don't sign."*
SAMPLE INTEGRITY	PDMA-signed sample request from licensed prescriber, locked storage, chain-of-custody, no diversion.	Leaving samples with receptionist; "stocking" beyond request.	*"Five starter cartons. PDMA signature here — confirming you're a licensed prescriber and these go to patients, not staff. Storage cabinet locked? Lot numbers recorded."*

THE SPECIALTY ACCESS SCORECARD (audit before every call):

• [ ] ZS AccessMonitor decile for this HCP (1-10, 10 = highest access barrier)
• [ ] Veeva CRM last 3 interactions — date, length, outcome, next-step logged
• [ ] Open Payments YTD for this HCP — total transfers of value, meal count, any near-cap exposure
• [ ] IQVIA Xponent / NPA prior Rx history — has this HCP ever prescribed (NRx + TRx trend last 12 months)?
• [ ] Formulary restrictions on dominant payer in territory (UHC + Aetna + Cigna + BCBS + Humana) — Tier, step-therapy, PA, quantity limit
• [ ] Patient hub enrollment trend — last 90-day hub enrollments from this HCP (zero = trust problem)
• [ ] REMS enrollment — is this HCP REMS-certified if drug requires it?
• [ ] Sample inventory on hand — does this HCP have current samples (lot # check)?
• [ ] Last MSL touch — has the HCP had a clinical (non-promotional) MSL engagement in last 6 months?
• [ ] Peer KOL connection — is there a peer KOL the HCP respects who has prescribed?

NEVER DO (the compliance + access-cratering behavior list):

• Discuss off-label use, even when HCP asks — single-sentence OPDP-reportable event
• Make payer coverage promises — *"we'll get it approved, don't worry"* — OIG-flag
• Disparage a competitor without FDA-approved head-to-head data — OPDP violation
• Hand over a reprint discussing an off-label use — treated identically to verbal promotion
• Leave samples without a PDMA-signed prescriber request — sample-integrity violation
• Offer meals over the policy cap (typically $25-$40/attendee) — Sunshine Act / OIG flag
• Skip the Open Payments sign-in sheet at lunch programs — untracked transfer of value
• Burn the OPEN minute on rapport — wastes 14% of the entire 7-min window
• Skip the PROBE — destroys the entire detail's clinical relevance
• Skip the CONFIRM — never surfaces the real barrier, can't deploy hub or market access
• Skip the CLOSE signature + hub one-pager + specific next-call date — collapses Step 5
• Disparage a manufacturer hub the HCP has had prior burns with — destroys trust permanently

THE OUTCOME LINE:

• Wins: OPEN + PROBE + SHARE + CONFIRM + CLOSE in sequence + Three Rails live + signed sample request + hub enrollment + scheduled next-call in Veeva → 54% detail-to-Rx-commit + zero compliance exposure + 78% PA approval rate where hub deployed + repeat HCP access
• Losses: Rapport OPEN + iPad feature-dump + no PROBE + closed *"any questions?"* + vague *"I'll swing back"* + samples left at reception → 15-20% commit + warning-letter risk + PDMA violation + HCP no-sees next visit + reputation damage in district

🎯 If You Only Remember One Thing

You're not selling the molecule — you're surfacing the patient on the doctor's panel who will benefit. The doctor wrote the script before you walked in; your job is just to make sure they remember to.

How This Training Sits Inside Your Specialty Commercial Stack

This is the foundational HCP-detail discipline — the 7-minute conversation that determines whether your territory hits NRx + TRx goal AND survives PhRMA Code + FDA OPDP + OIG + Sunshine Act audits. It does not replace MSL scientific exchange, market access strategy, or patient hub operations — it composes from all of them.

The 60-Minute Meeting Flow

Manager Coaching Loop

📚 Sources, Frameworks, And Research Cited

The 7-Minute Detail framework, the PhRMA Code Three Rails compliance frame, and the ZS AccessMonitor 79%→44% rep-access benchmark draw on a specific body of pharmaceutical commercial + regulatory research. A DSM should be ready to cite these by name.

Regulatory + compliance framework. PhRMA Code on Interactions with Healthcare Professionals (2022 update) — the industry-wide standard for educational-meal caps, speaker programs, samples, consulting, and gifts. FDA OPDP (Office of Prescription Drug Promotion) — publicly indexed warning letters and untitled letters define the off-label enforcement floor; current enforcement focus includes social-media promotion, off-label reprint distribution, and misleading comparator claims.

OIG (Office of Inspector General) Compliance Program Guidance for Pharmaceutical Manufacturers (September 2023 final guidance) — anti-kickback statute application, speaker-program risk factors, fair-market-value standards, and exclusion-list screening. CMS Open Payments / Physician Payments Sunshine Act — manufacturer reporting requirement on every transfer of value to a covered recipient ≥$10 (meals, honoraria, samples, consulting fees), publicly searchable at openpaymentsdata.cms.gov.

PDMA (Prescription Drug Marketing Act of 1987) + 21 CFR Part 203 — federal sample distribution law: signed prescriber requests, locked storage, chain-of-custody, anti-diversion. FDA REMS (Risk Evaluation and Mitigation Strategies) — for drugs requiring enrollment + training + safe-use documentation (clozapine REMS, isotretinoin iPLEDGE, mifepristone REMS, opioid REMS).

Rep-access + commercial-effectiveness research. ZS Associates AccessMonitor + ePharma Physician 2024-2025 — published HCP rep-access trend data (the 79% in 2008 → 44% in 2025 decline), detail-length benchmarks (7 min specialty, 4 min PCP), no-see-physician categorization, channel-preference shifts.

Veeva Pulse — quarterly benchmark report on rep + HCP engagement across the Veeva CRM customer base (≈80% of pharma reps globally). Doctors.com + Sermo + Medscape — physician-side surveys on rep-engagement quality and preferred channels.

Prescriber + claims data sources. IQVIA Xponent + IQVIA NPA Audit + IQVIA DDD — prescriber-level Rx data (NRx + TRx + dispense-channel breakdown). Symphony Health PHAST + IPSA — competing prescriber-level data set. Veeva Link KOL Data — HCP-affiliation, publications, congress speaking, KOL-network mapping.

Komodo Health + Trilliant + Definitive Healthcare — adjacent specialty-care HCP affiliation + patient-flow data.

Specialty pharmacy + payer access. CVS Specialty + Walgreens Specialty + Accredo (ESI/Cigna) + Optum Specialty (UHC) + AllianceRx Walgreens Prime — the dispensing-channel infrastructure for specialty drugs; rep interactions feed into hub-to-specialty-pharmacy patient-routing.

Manufacturer patient hub services — Pfizer Patient Connect + AstraZeneca Access 360 + Bristol-Myers Squibb Access Support + Novartis Patient Support + AbbVie Access Solutions — the operational PA-support + patient-assistance-program + nurse-triage layer that converts HCP commitment into actual fills.

Industry trade + benchmark publications. Endpoints News + FiercePharma + BioPharma Dive + STAT + Pink Sheet + PharmaVoice + Medical Marketing & Media (MM+M) for commercial benchmarking, launch case studies, OPDP enforcement coverage, and post-launch competitive analysis. PhRMA + BIO (Biotechnology Innovation Organization) + NACDS (National Association of Chain Drug Stores) trade association data on industry policy + compliance trends.

Exemplar specialty launches referenced in the training (without endorsement) — Vraylar (cariprazine, AbbVie) atypical antipsychotic, Trikafta (elexacaftor/tezacaftor/ivacaftor, Vertex) cystic fibrosis triple therapy, Dupixent (dupilumab, Sanofi/Regeneron) atopic dermatitis/asthma/EoE, Ozempic / Wegovy (semaglutide, Novo Nordisk) GLP-1 diabetes/obesity, Keytruda (pembrolizumab, Merck) anti-PD-1 across oncology indications, Vyvgart (efgartigimod, Argenx) generalized myasthenia gravis.

Each represents a leading specialty-pharma launch with documented commercial playbooks adapted to the 7-Minute Detail discipline.

The 7-Minute Detail framework composes on the original AstraZeneca + Pfizer + Merck rep-training curricula from the 1990s-2010s and the post-COVID rep-access reality documented by ZS Associates. The Three Rails frame is the operational floor distilled from FDA OPDP enforcement actions + OIG compliance program audits + Sunshine Act reporting requirements + PDMA sample regulations + recent DOJ settlements (multi-billion-dollar manufacturer settlements 2009-2024 define what NOT to do).

📊 The Numbers Behind The Training

The cold open lands harder when the DSM can quote real benchmarks. The tables below pull from ZS Associates AccessMonitor 2024-2025 + ePharma Physician + Veeva Pulse + IQVIA + JD Power physician surveys + published OPDP enforcement summaries + DOJ pharma settlement records.

HCP Rep-Access Decline (ZS Associates AccessMonitor)

Specialty Detail Length By Specialty (ZS 2024-2025)

Detail-to-Rx-Commit Conversion By Discipline Tier

Why HCPs Decline To Prescribe After Detail (Veeva Pulse + Sermo Surveys)

OPDP + DOJ Enforcement Cost (2009-2024 Notable Settlements)

Sunshine Act / Open Payments Reporting Thresholds

Sample Distribution (PDMA / 21 CFR Part 203 Compliance Audit)

7-Minute Detail Step-Adoption Curve (Reps Running All 5 Steps)

Pattern: Step 2 (PROBE) and Step 4 (CONFIRM) are the hardest to install — most reps default to feature-dump and *"any questions?"*. The weekly Veeva CRM call-note audit by the DSM is the single biggest predictor of cohort NRx lift at 90 days per Veeva Pulse + IQVIA-correlated commercial dashboards.

The Three Rails frame adopts faster (most reps reach 80%+ adherence by week 6) because compliance pressure from corporate is direct and the consequences (OPDP, individual termination) are existential.

⚠️ Counter-Case: When The Framework Fails

Failure Mode 1 -- Rep Burns OPEN on Rapport

*"How was your weekend? How are the kids?"* — wastes 30-45 seconds of a 7-minute window. HCP mentally checks out. Per ZS 2024, this is the #1 cited "rep waste of time" complaint. Coach: drill the verbatim OPEN until reflex. Sixty seconds. Permission ask. Verbal yes. Then iPad.

Failure Mode 2 -- Skips Step 2 PROBE

Rep opens iPad and starts presenting features. Per Veeva Pulse, 41% of non-commits trace to PROBE-skip. Without the patient-finder probe, the SHARE message has nothing to anchor to. Coach: verbatim patient-finder probe in pairs before leaving the room.

Failure Mode 3 -- Goes Off-Label When HCP Asks

HCP asks about a sub-population not in the FDA-approved indication. Rep answers. Single sentence = OPDP-reportable event + potential termination + potential DOJ exposure for systemic patterns. Coach: MSL-redirect verbatim, drilled until reflex. *"Outside the indication — let me have our MSL reach out today."* Zero tolerance.

Failure Mode 4 -- Makes Coverage Promises

*"We'll get it covered, don't worry."* — manufacturer cannot guarantee payer coverage; OIG-flag + fair-balance issue. Coach: drill *"I can't promise UHC will approve — current PA approval rate is 78%, average turnaround is 18 days."* Statistics, not promises.

Failure Mode 5 -- Disparages Competitor Without Head-to-Head Data

*"Enhertu has worse safety in HER2-low."* — without FDA-approved head-to-head trial data, OPDP violation. Coach: acknowledge competitor strength where data shows it; reframe to the specific sub-population where the rep's drug data is strongest. Honest comparison defensible; disparagement is not.

Failure Mode 6 -- Leaves Samples Without PDMA-Signed Request

Receptionist accepts the samples; no prescriber signature. PDMA violation — and the sample-request audit trail is what the manufacturer's compliance team and FDA inspectors look at. Coach: zero samples without signed request. If prescriber is unavailable, samples leave with the rep, return on next visit.

Failure Mode 7 -- Skips Open Payments Sign-In At Educational Meal

Untracked transfer of value ≥$10. Sunshine Act non-compliance. Coach: sign-in sheet at every educational meal program. Track attendance + meal value per attendee. Submit to compliance same day.

Failure Mode 8 -- Vague Close ("I'll Be Back When I'm In The Area")

No specific date. No signed sample request. No hub enrollment one-pager. Step 5 collapsed. Per Veeva, vague closes produce zero follow-up 71% of the time. Coach: verbatim close with specific date + signed paper + hub one-pager. Every detail. Every time.

Failure Mode 9 -- Disparages a Prior Manufacturer Hub the HCP Has Been Burned By

HCP says *"I've had bad experiences with manufacturer hubs."* Rep says *"that was a different drug, not us"* dismissively. Trust dies permanently. Coach: acknowledge the burn, name the specific operational change (*"we restaffed the regional team in March 2024, current PA appeal success is 84%"*), let the numbers earn back trust.

Failure Mode 10 -- DSM Doesn't Audit Weekly Veeva CRM Call Notes

Kills 65-75% of HCP-detail training rollouts. Per Veeva Pulse 2024, ~30-day half-life un-coached. Reps revert to feature-dump + "any questions?" close by week 4. Coach: one detail per rep per week, reviewed in 1:1, marked for 5-step + 3-Rail adherence. Non-negotiable.

Common DSM + Brand Team Objections

1. "My reps already know how to detail." Pull 90 days of NRx per HCP per rep. Bottom-quartile reps know the iPad — top reps run the 5-step + 3-Rail with the Specialty Access Scorecard.

2. "Compliance and Rx growth are in tension." Backwards. Top-quartile reps (48-72% commit) have the LOWEST OPDP / OIG findings. Bottom-quartile reps generate compliance investigations.

3. "AccessMonitor data is depressing — why train into a shrinking window?" The 7-min window is permanent. The reps who script the load-bearing 90 seconds convert at 2x cohort inside that window. Shrinking access makes discipline MORE valuable, not less.

4. "Rare disease reps don't need this — they get longer details." Partly true (9 min vs 7), and they need MORE discipline because there are <2,000 prescribers nationally per orphan drug and every detail matters.

5. "Oncology academic reps work with KOLs — different game." Same 5 steps. The KOL respects them MORE for the discipline. The KOL CUTS OFF the rep who feature-dumps faster than the community physician.

6. "Senior reps don't need this." Senior reps came up pre-2019 when access was 55%+ and details ran 12-15 min. The post-COVID 7-minute reality requires re-skilling.

7. "How do I know it's working?" Three 90-day signals: NRx +30-50% per rep / detail-to-commit rate +15-25 pts / ZS AccessMonitor decile lift +1-2 in territory / zero OPDP findings / sample-request signed-rate above 85%.

When To Run A Second Time

Re-run every 90 days with fresh unconverted-HCP audits + updated OPDP enforcement actions + updated PhRMA Code revisions. Rotate role-plays from last quarter's unconverted high-decile HCPs. Third run, swap archetypes — REMS-enrolled drug requiring HCP enrollment verification, biosimilar-pressured biologic, rare-disease orphan-drug with <500 national prescribers, ophthalmology drug with practice-administered injection workflow, hospital-system pharmacy-and-therapeutics (P&T) committee detail, ACO/value-based-care-contracted health system.

🔗 Related Pulse Content

Tenth entry in Pulse Sales Trainings (/sales-trainings/) and fourth industry-specific training after st0007 (orthopedic medical device sales), st0008 (residential real estate listing presentations), and st0009 (automotive F&I). st0001-st0006 covered B2B SaaS sales motions that translate across industries; st0007-forward pivots to industry-by-industry coverage. st0010 is specialty pharmaceutical HCP detailing — the most-regulated 7-minute conversation in commercial sales, and the territory where rare-disease, oncology, immunology, hematology, neurology, and ophthalmology brand teams fight for NRx growth inside the PhRMA Code + FDA OPDP + OIG + Sunshine Act + PDMA + REMS enforcement perimeter.

Companion industry-specific entries planned: st0011 commercial real estate brokerage, st0012 property management + multifamily leasing, st0013 title insurance + closing services, st0014 new construction + builder sales reps, st0015 real estate investment sales (fix-and-flip / BRRRR / syndication), st0016 real estate tech vendor sales (CRM / MLS / iBuyer / proptech), st0017 medical-device adjacencies (cardiology + endovascular), st0018 biotech KAM (key account management) for hospital health systems, st0019 specialty pharmacy hub-services sales, st0020 payer / market-access account director conversations with pharmacy benefit managers (PBMs).

Each follows the same six-section structure.

Cross-references to st0001-st0006 SaaS foundation arc translated for pharma detailing: st0001 discovery → Step 2 PROBE (patient-finder question replaces SaaS discovery); st0002 single-threading → MSL is the second thread for off-label scientific exchange; st0003 objection recovery → Step 4 CONFIRM surfaces real barriers (formulary, PA, REMS); st0004 cold-call opener → Step 1 OPEN (60-sec scripted permission ask); st0005 demo discipline → Step 3 SHARE (ONE on-label message tied to patient profile, FDA-approved detail aid); st0006 pricing → CONFIRM surfaces patient cost as a real barrier, hub services as the response.

A rep who internalized st0001-st0006 absorbs the pharma-detailing overlay 2x as fast, because the discipline of verbatim language on load-bearing moments transfers exactly.

Cross-reference to st0007 + st0008 + st0009 — what transfers: the discipline of verbatim language on load-bearing moments + recording-or-CRM-reviewed coaching cadence transfers exactly. Where st0007 made surgeons hear OR + Evidence + Outcome diagnostics verbatim, st0008 made sellers hear PROOF + Fee 4-line + PRICE-as-range verbatim, and st0009 made customers hear 9-Step F&I verbatim, st0010 makes HCPs hear OPEN + PROBE + CONFIRM + CLOSE verbatim.

Top reps script the load-bearing moments and improvise the rest. What does NOT transfer: pharma has the hardest individual-rep compliance overlay of any industry covered so far — a single off-label sentence in field is a fireable + DOJ-reportable event, in a way the medical-device evidence-pyramid + real-estate-NAR-settlement + auto-F&I-CARS-Rule frames are merely demanding.

Adjacent Pulse Knowledge Library entries: PhRMA Code 2022 primer + FDA OPDP warning + untitled letter history + OIG Compliance Program Guidance Sept 2023 walkthrough + Sunshine Act / Open Payments reporting checklist + PDMA sample distribution audit template + REMS program list + ZS AccessMonitor methodology + Veeva Pulse benchmarking + IQVIA Xponent vs Symphony PHAST comparison + specialty pharmacy channel guide (CVS Specialty + Walgreens Specialty + Accredo + Optum Specialty + AllianceRx) + manufacturer patient hub services comparison (Pfizer Patient Connect + AZ Access 360 + BMS Access Support + Novartis Patient Support + AbbVie Access Solutions).

q9601 fractional CFO maps onto the brand-level commercial-effectiveness conversation the VP Sales has with the launch-team CFO before approving any new field-force expansion.

Frameworks for deeper read: PhRMA Code (phrma.org/codes-and-guidelines) + FDA OPDP warning letters (fda.gov/drugs/warning-letters-and-notice-violation-letters) + OIG CPG (oig.hhs.gov/compliance) + CMS Open Payments (openpaymentsdata.cms.gov) + PDMA 21 CFR Part 203 (ecfr.gov) + FDA REMS (fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems) + ZS AccessMonitor (zs.com/insights) + Veeva Pulse (veeva.com) + IQVIA commercial solutions (iqvia.com) + industry trade press Endpoints News + FiercePharma + BioPharma Dive + STAT + Pink Sheet + MM+M + PharmaVoice.

Hub: /sales-trainings. Canonical: /sales-trainings/st0010.